Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR somatic variants status confers therapeutic sensitivity to Atezolizumab in patients with Non-Small Cell Lung Cancer.
The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.
This statement is based on a regulatory approval from the European Medicines Agency:
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.